Sang Jun Lee

Sang Jun Lee

Auto-generated profile, based on publicly available information

Sang Jun Lee

Division of Cardiology, Department of Internal Medicine, Wonju Severance Christian Hospital, Yonsei University Wonju College of Medicine, Wonju, Republic of Korea

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 December 2020 in European Journal of Preventive Cardiology
Verified
Journal Article
Closed access
PDF file
SKSu Yong Kim
Su Yong Kim
TGTae Hwa Go
Tae Hwa Go
JLJun Hyeok Lee
Jun Hyeok Lee
JMJin Sil Moon
Jin Sil Moon
DKDae Ryong Kang
Dae Ryong Kang
SASung Gyun Ahn
Sung Gyun Ahn
To investigate sex differences in the association of metabolic syndrome (MetS) and/or low-density lipoprotein cholesterol (LDL-C) with the incidence of cardiovascular and cerebrovascular disease (CCVD). A total of 4 702 458 individuals, aged between 40 and 70, without a previous diagnosis of CCVD, underwent at least two health screenings between 2009 and 2011. Of them, 4 193 878 individuals (48.6% women) fulfilled the study requirements. The main outcome measured was the incidence of CCVD. By the end of 2017, 68 921 CCVD events occurred. Men in high LDL-C only, MetS only, and both MetS and high LDL-C groups had higher risks of CCVD. Women in MetS only and both MetS and high LDL-C groups, but not those in high LDL-C only group, had higher risks of CCVD than those in the reference group. The effect of the interaction between the presence of MetS and high LDL-C levels on the primary outcome was found among women (P for interaction 0.016) but not among men (P for interaction 0.897). A combination of MetS and LDL-C > 3.4 mmol/L increased the risk of CCVD as compared to MetS or LDL-C > 3.4 mmol/L alone in both men and women. Metabolic syndrome confers an increased risk of CCVD irrespective of sexes; LDL-C > 3.4 mmol/L alone has a greater influence on CCVD occurrence in men than in women. Metabolic syndrome and high LDL-C beget a synergistically detrimental impact on the incidence of CCVD in both men and women. Treatment of dyslipidaemia and metabolic syndrome should be tailored according to patient characteristics.

1 January 2019 in Korean Circulation Journal
Verified
Journal Article
Open access
SASung Gyun Ahn
Sung Gyun Ahn
SLSang Jun Lee
Sang Jun Lee

24 April 2026 in JMIR Medical Informatics
Verified
Journal Article
Open access
SLSungjae Lee
Sungjae Lee
JSJung-Woo Son
Jung-Woo Son
SKSung-Ai Kim
Sung-Ai Kim
MAMin-Soo Ahn
Min-Soo Ahn
SLSang Jun Lee
Sang Jun Lee
YPYoung Jun Park
Young Jun Park
Background: Artificial intelligence–augmented electrocardiogram (AI-ECG) models for detecting left ventricular systolic dysfunction (LVSD) often exhibit degraded performance in patients with comorbidities. Objective: This study aimed to introduce and validate a recalibration method using longitudinal patient data to enhance prediction accuracy and simulate its clinical utility for ongoing monitoring. Methods: We conducted a multicenter, retrospective cohort study using data from 2 hospitals in Korea. A dataset of paired transthoracic echocardiograms (TTEs) and electrocardiograms (ECGs) matched within a 2-week interval was constructed, separating pairs into baseline (first for each patient) and follow-up assessments. In addition to conventional supervised learning, we developed a patient-wise recalibration strategy that incorporated historical left ventricular ejection fraction measurements and prior AI-ECG outputs to adjust for future predictions, thus empirically mitigating confounding effects. Pretraining was also implemented to enhance the model’s performance. Results: The recalibrated 12-lead DeepECG LVSD model achieved an area under the receiver operating curve of 0.956 (95% CI 0.946‐0.965) for internal validation and 0.940 (95% CI 0.936‐0.945) for external validation of follow-up TTE-ECG pairs. The uncalibrated 12-lead DeepECG LVSD model also showed modest performance, with an area under the receiver operating curve of 0.953 (95% CI 0.941‐0.965) in the internal validation and 0.947 (95% CI 0.943‐0.951) in the external validation when tested on baseline TTE-ECG pairs. Recalibration yielded statistically significant improvements in the 12-lead DeepECG LVSD models ( P <.001), with enhanced and more balanced performance across all clinical subgroups. Conclusions: Patient-wise recalibration improved accuracy and consistency across various comorbidities by mitigating performance degradation and bias. This broadens the application of AI-ECG for LVSD detection from low-risk screening to high-risk longitudinal monitoring.